6 products were found matching "184475-35-2"!

Gefitinib is an EGFR inhibitor (IC50s = 0.023-0.079 µM). It inhibits colony formation of GEO colon, ZR-75-1 and MCF-10A breast, and OVCAR-3 ovarian cancer cell lines in soft agar assays (IC50s = 0.2-0.4 µM). Gefitinib (0.1 to 1 µM) induces apoptosis and inhibits EGFR autophosphorylation in the same cells. In vivo,...

Description: Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S...

Soluble in DMSO or ethanol. Gefitinib is a selective, orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. In NR6wtEGFR and NR6W cells, it inhibits Tyr1173, Tyr992, Tyr1173 and Tyr992 with IC(50) values of 37nM, 37nM, 26nM and 57nM, respectively. Target: EGFR , Kinase Group: RTK ,...

EGFR tyrosine kinase inhibitor that binds to the ATP-binding site of the enzyme. The functions of the EGFR tyrosine kinase in activating the Ras signal transduction cascade and malignant cell growth are thus inhibited. It has been shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating...

Gefitinib is an EGFR inhibitor (IC50s = 0.023-0.079 µM). It inhibits colony formation of GEO colon, ZR-75-1 and MCF-10A breast, and OVCAR-3 ovarian cancer cell lines in soft agar assays (IC50s = 0.2-0.4 µM). Gefitinib (0.1 to 1 µM) induces apoptosis and inhibits EGFR autophosphorylation in the same cells. In vivo,...